{{Drugbox
| IUPAC_name = 7-(4-methylpiperazin-1-yl)-3''H''-1,3-benzoxazol-2-one
| image = Pardoprunox.png
| width = 150px

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 269718-84-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6918524
| ChemSpiderID = 5293721
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5R72CHP32S

<!--Chemical data-->
| C=12 | H=15 | N=3 | O=2 
| molecular_weight = 269.73 g/mol
| smiles = Cl.O=C2Oc1c(cccc1N2)N3CCN(C)CC3
}}

'''Pardoprunox''' ([[International Nonproprietary Name|INN]]) (code name '''SLV-308''') is an [[antiparkinsonian]] [[drug]] developed by [[Solvay (company)|Solvay]] for the treatment of [[Parkinson's disease]] that reached [[Clinical trial#Phase III|phase III]] [[clinical trial]]s before being discontinued.<ref name="pmid14619412">{{cite journal | author = Wolf WA | title = SLV-308. Solvay | journal = Current Opinion in Investigational Drugs (London, England : 2000) | volume = 4 | issue = 7 | pages = 878–82 |date=July 2003 | pmid = 14619412 | doi = | url = }}</ref><ref name="urlSearch of: pardoprunox - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=pardoprunox | title = Search of: pardoprunox - List Results - ClinicalTrials.gov | work = | accessdate = }}</ref><ref name="pmid20198713">{{cite journal  |vauthors=Bronzova J, Sampaio C, Hauser RA, etal | title = Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease | journal = Movement Disorders : Official Journal of the Movement Disorder Society | volume = 25| issue = 6| pages = NA–NA|date=March 2010 | pmid = 20198713 | doi = 10.1002/mds.22948 }}</ref>[http://adisinsight.springer.com/drugs/800014329] It was also being investigated for the treatment of [[major depression|depression]] and [[anxiety]] but these indications appear to have been abandoned as well.<ref name="pmid14619412"/>

Pardoprunox acts as a [[D2 receptor|D<sub>2</sub>]] (pK<sub>i</sub> = 8.1) and [[D3 receptor|D<sub>3</sub> receptor]] (pK<sub>i</sub> = 8.6) [[partial agonist]] (IA = 50% and 67%, respectively) and [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] (pK<sub>i</sub> = 8.5) [[full agonist]] (IA = 100%).<ref name="pmid14619412"/><ref name="pmid17001660">{{cite journal  |vauthors=Glennon JC, Van Scharrenburg G, Ronken E, etal | title = In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist | journal = Synapse | volume = 60 | issue = 8 | pages = 599–608 |date=December 2006 | pmid = 17001660 | doi = 10.1002/syn.20330 }}</ref> It also binds to [[D4 receptor|D<sub>4</sub>]] (pK<sub>i</sub> = 7.8), [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]] (pK<sub>i</sub> = 7.8), [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]] (pK<sub>i</sub> = 7.4), and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s (pK<sub>i</sub> = 7.2) with lower [[affinity (pharmacology)|affinity]].<ref name="pmid14619412"/><ref name="pmid17001660"/> Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain [[side effect]]s like [[dyskinesia]] and [[psychosis]].<ref name="pmid17001660"/><ref name="pmid18806903">{{cite journal | vauthors = Gottwald MD, Aminoff MJ | title = New frontiers in the pharmacological management of Parkinson's disease | journal = Drugs of Today (Barcelona, Spain : 1998) | volume = 44 | issue = 7 | pages = 531–45 |date=July 2008 | pmid = 18806903 | doi = 10.1358/dot.2008.44.7.1217105 | url = http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1217105}}</ref>

==See also==
* [[Aripiprazole]]
* [[Bifeprunox]]
* [[Pimavanserin]]

==References==
{{Reflist|2}}

==Further reading==
* {{cite journal  |vauthors=Hauser RA, Bronzova J, Sampaio C, etal | title = Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease | journal = European Neurology | volume = 62 | issue = 1 | pages = 40–8 | year = 2009 | pmid = 19407454 | doi = 10.1159/000216839 | url = http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000216839}}
* {{cite journal  |vauthors=Bronzova J, Sampaio C, Hauser RA, etal | title = Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease | journal = Movement Disorders : Official Journal of the Movement Disorder Society | volume = 25| issue = 6| pages = NA–NA|date=March 2010 | pmid = 20198713 | doi = 10.1002/mds.22948 }}

{{Antiparkinson}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Piperazines}}

[[Category:5-HT1A agonists]]
[[Category:Dopamine agonists]]
[[Category:Piperazines]]
[[Category:Benzoxazoles]]
[[Category:Carbamates]]


{{nervous-system-drug-stub}}